135 related articles for article (PubMed ID: 14615468)
1. Pharmacokinetics and pharmacodynamics of mesna-mediated plasma cysteine depletion.
Smith PF; Booker BM; Creaven P; Perez R; Pendyala L
J Clin Pharmacol; 2003 Dec; 43(12):1324-8. PubMed ID: 14615468
[TBL] [Abstract][Full Text] [Related]
2. Intravenous ifosfamide/mesna is associated with depletion of plasma thiols without depletion of leukocyte glutathione.
Pendyala L; Creaven PJ; Schwartz G; Meropol NJ; Bolanowska-Higdon W; Zdanowicz J; Murphy M; Perez R
Clin Cancer Res; 2000 Apr; 6(4):1314-21. PubMed ID: 10778956
[TBL] [Abstract][Full Text] [Related]
3. Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy.
Pendyala L; Schwartz G; Smith P; Zdanowicz J; Murphy M; Hausheer F
Cancer Chemother Pharmacol; 2003 May; 51(5):376-84. PubMed ID: 12682786
[TBL] [Abstract][Full Text] [Related]
4. Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study.
You B; Tranchand B; Girard P; Falandry C; Ribba B; Chabaud S; Souquet PJ; Court-Fortune I; Trillet-Lenoir V; Fournel C; Tod M; Freyer G
Lung Cancer; 2008 Nov; 62(2):261-72. PubMed ID: 18442869
[TBL] [Abstract][Full Text] [Related]
5. Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide.
Mace JR; Keohan ML; Bernardy H; Junge K; Niebch G; Romeis P; Thoma A; Wagner T; Mueller U; Demetri G; Baker LH
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5829-34. PubMed ID: 14676103
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites.
Verschraagen M; Boven E; Ruijter R; van der Born K; Berkhof J; Hausheer FH; van der Vijgh WJ
Clin Pharmacol Ther; 2003 Aug; 74(2):157-69. PubMed ID: 12891226
[TBL] [Abstract][Full Text] [Related]
7. Possible (enzymatic) routes and biological sites for metabolic reduction of BNP7787, a new protector against cisplatin-induced side-effects.
Verschraagen M; Boven E; Torun E; Hausheer FH; Bast A; van der Vijgh WJ
Biochem Pharmacol; 2004 Aug; 68(3):493-502. PubMed ID: 15242815
[TBL] [Abstract][Full Text] [Related]
8. Depletion of total cysteine, glutathione, and homocysteine in plasma by ifosfamide/mesna therapy.
Lauterburg BH; Nguyen T; Hartmann B; Junker E; Küpfer A; Cerny T
Cancer Chemother Pharmacol; 1994; 35(2):132-6. PubMed ID: 7987989
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of BNP7787 and its metabolite mesna in plasma and ascites: a case report.
Verschraagen M; Boven E; Zegers I; Hausheer FH; Van der Vijgh WJ
Cancer Chemother Pharmacol; 2003 Jun; 51(6):525-9. PubMed ID: 12750838
[TBL] [Abstract][Full Text] [Related]
10. Effect of ifosfamide treatment on glutathione and glutathione conjugation activity in patients with advanced cancers.
Mulders TM; Keizer ; Ouwerkerk J; van der Velde EA; Breimer DD; Mulder GJ
Clin Cancer Res; 1995 Dec; 1(12):1525-36. PubMed ID: 9815953
[TBL] [Abstract][Full Text] [Related]
11. Urine mesna excretion after intravenous and oral dosing in ifosfamide-treated children.
Goren MP; Epelman S; Bush DA
Cancer Chemother Pharmacol; 2004 Sep; 54(3):237-40. PubMed ID: 15184993
[TBL] [Abstract][Full Text] [Related]
12. WR-2721 (amifostine) infusion in patients with Ewing's sarcoma receiving ifosfamide and cyclophosphamide with mesna: drug and thiol levels in plasma and blood cells, a Pediatric Oncology Group study.
Souid AK; Fahey RC; Dubowy RL; Newton GL; Bernstein ML
Cancer Chemother Pharmacol; 1999; 44(6):498-504. PubMed ID: 10550571
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group Study.
Veal GJ; Cole M; Errington J; Parry A; Hale J; Pearson AD; Howe K; Chisholm JC; Beane C; Brennan B; Waters F; Glaser A; Hemsworth S; McDowell H; Wright Y; Pritchard-Jones K; Pinkerton R; Jenner G; Nicholson J; Elsworth AM; Boddy AV;
Clin Cancer Res; 2005 Aug; 11(16):5893-9. PubMed ID: 16115931
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic modelling of ifosfamide administered by continuous infusion on 5 days at the dose of 6 g/m2.
Passe P; Delepine N; Arnaud P; Urien S; Delepine G; Traoré F; Desbois JC; Brion F
Anticancer Res; 1999; 19(1B):837-42. PubMed ID: 10216502
[TBL] [Abstract][Full Text] [Related]
16. Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK).
Cerny T; Leyvraz S; von Briel T; Küpfer A; Schaad R; Schmitz SF; Honegger P; Sessa C; Brunner J; Boddy AV
Ann Oncol; 1999 Sep; 10(9):1087-94. PubMed ID: 10572607
[TBL] [Abstract][Full Text] [Related]
17. Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjects.
Goren MP; Houle JM; Bush DA; Li JT; Newman CE; Brade WP
Clin Cancer Res; 1998 Oct; 4(10):2313-20. PubMed ID: 9796960
[TBL] [Abstract][Full Text] [Related]
18. Ifosfamide and mesna.
Schoenike SE; Dana WJ
Clin Pharm; 1990 Mar; 9(3):179-91. PubMed ID: 2107997
[TBL] [Abstract][Full Text] [Related]
19. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
[TBL] [Abstract][Full Text] [Related]
20. Mesna inactivates platinum agents in vitro.
Wolff JE; Egeler RM; Anderson R; Ujack E; Iceton S; Coppes MJ
Anticancer Res; 1998; 18(6A):4077-81. PubMed ID: 9891448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]